Insights

Strategic partnerships IDEAYA is actively engaged in collaborations with industry leaders such as Genentech to evaluate IDE892 in MTAP-deleted KRAS G12D-mutant pancreatic cancer, signaling strong opportunities for co-development or sponsored research deals with large pharma seeking precision oncology assets.

Clinical momentum Recent leadership expansion to appoint Dr. Michael White as President, R&D, along with ongoing Phase 1/2 trials for IDE892, indicate a company rapidly advancing its pipeline, presenting potential for clinical collaboration, CRO support, and translational research partnerships.

Financial footing With a substantial funding base and a revenue range in the tens of millions alongside a multi-billion dollar market cap trajectory, IDEAYA presents a credible partner for strategic investments, grant-backed programs, or milestone-driven collaborations.

Targeted biology Focus on synthetic lethality and MTAP-deleted, KRAS-mutant contexts positions IDEAYA to attract specialized platform or diagnostic collaboration opportunities, including companion diagnostics development and biomarker-driven study design services.

Recognition potential Industry recognition such as melanoma leadership awards and a high-profile corporate collaboration track record enhance credibility for enterprise sales motions, enabling introductions to senior decision-makers in oncology-focused portfolios and ecosystem partnerships.

Similar companies to IDEAYA Biosciences

IDEAYA Biosciences Tech Stack

IDEAYA Biosciences uses 8 technology products and services including Matomo, Databricks, Salesforce, and more. Explore IDEAYA Biosciences's tech stack below.

Media & News

IDEAYA Biosciences's Email Address Formats

IDEAYA Biosciences uses at least 3 email formats:
IDEAYA Biosciences Email FormatsExamplePercentage
FLast@ideayabio.comJDoe@ideayabio.com
98%
Last@ideayabio.comDoe@ideayabio.com
1%
FL@ideayabio.comJD@ideayabio.com
1%

Frequently Asked Questions

What is IDEAYA Biosciences's phone number?

Minus sign iconPlus sign icon
You can contact IDEAYA Biosciences's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is IDEAYA Biosciences's stock symbol?

Minus sign iconPlus sign icon
IDEAYA Biosciences is a publicly traded company; the company's stock symbol is IDYA.

What is IDEAYA Biosciences's official website and social media links?

Minus sign iconPlus sign icon
IDEAYA Biosciences's official website is ideayabio.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does IDEAYA Biosciences generate?

Minus sign iconPlus sign icon
As of October 2026, IDEAYA Biosciences's annual revenue is estimated to be $10M - $25M.

What is IDEAYA Biosciences's SIC code and NAICS code?

Minus sign iconPlus sign icon
IDEAYA Biosciences's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does IDEAYA Biosciences have currently?

Minus sign iconPlus sign icon
As of October 2026, IDEAYA Biosciences has approximately 282 employees across 3 continents, including North America, Asia and South America. Key team members include Chief Development Officer: T. R., Vice President Of Sales: J. E. and Owner And Principal Consultant: J. V. E. Explore IDEAYA Biosciences's employee directory with LeadIQ.

What industry does IDEAYA Biosciences belong to?

Minus sign iconPlus sign icon
IDEAYA Biosciences operates in the Biotechnology Research industry.

What technology does IDEAYA Biosciences use?

Minus sign iconPlus sign icon
IDEAYA Biosciences's tech stack includes Matomo, Databricks, Salesforce, Adobe Experience Cloud, Informatica, ADP Workforce Now, WP Engine and Adobe Creative Suite.

What is IDEAYA Biosciences's email format?

Minus sign iconPlus sign icon
IDEAYA Biosciences's email format typically follows the pattern of FLast@ideayabio.com. Find more IDEAYA Biosciences email formats with LeadIQ.

How much funding has IDEAYA Biosciences raised to date?

Minus sign iconPlus sign icon
As of October 2026, IDEAYA Biosciences has raised $1B in funding. The last funding round occurred on Jun 08, 2026 for $263M.

When was IDEAYA Biosciences founded?

Minus sign iconPlus sign icon
IDEAYA Biosciences was founded in 2015.
IDEAYA Biosciences logo

IDEAYA Biosciences

Biotechnology ResearchCalifornia, United States201-500 Employees

IDEAYA Biosciences is a biotechnology company focused on oncology and precision medicine. It pursues discovery and development of targeted therapeutics for patient populations defined by molecular diagnostics, with a primary emphasis on synthetic lethality as a class of precision medicine targets.

Headquartered in South San Francisco, California, IDEAYA is a mid-sized firm focused on advancing this agenda. In June 2026, the company announced the launch of IDE892, a potential best-in-class MTA-Cooperative PRMT5 inhibitor, initiating a Phase 1/2 study in MTAP-deleted pancreatic and lung cancers.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
IDYA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
201-500

Section iconFunding & Financials

  • $1B

    IDEAYA Biosciences has raised a total of $1B of funding over 8 rounds. Their latest funding round was raised on Jun 08, 2026 in the amount of $263M as a Post IPO Equity.

  • $10M - $25M

    IDEAYA Biosciences's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.